Boxed warning added to Fansidar labeling.
D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000517:prevention & control; D011356:Product Labeling; D011739:Pyrimethamine / Q000009:adverse effects* / Q000627:therapeutic use; D013413:Sulfadoxine / Q000009:adverse effects* / Q000627:therapeutic use; D013424:Sulfanilamides / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D013424:Sulfanilamides; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine